US Patent 11672800 Combination therapies with EHMT2 inhibitors
Patent 11672800 was granted and assigned to Epizyme on June, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 4 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 14 Jun, 2023
Golden AI
Edits made to:
Infobox (+22 properties)
Article (+430 characters)
US Patent 11672800 Combination therapies with EHMT2 inhibitors
Article
The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
116728000
Date of Patent
June 13, 2023
0Patent Application Number
166068330
Date Filed
April 20, 2018
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11672800 Combination therapies with EHMT2 inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.